Cozaar gains renal protection licence

pharmafile | October 21, 2003 | News story | |   

Merck Sharpe & Dohme's Cozaar has gained a new UK licence for renal protection in patients with type II diabetes and nephropathy.

The approval strengthens Cozaar's place in the highly competitive market and follows a boost from NICE's recommendation of the angiotensin II receptor blocker (ARB) class as first line treatment for the conditions.

In July this year Bristol Myers-Squibb and Sanofi-Synthlabo rival product Aprovel became the first ARB to gain a European licence to treat renal disease in diabetic patients, and is tipped to lead the field.

Datamonitor estimates that ARBs will eclipse all other hypertension treatments by 2008. Sales of the drugs currently represent 17% of all antihypertensive sales, but their share is expected to rise to 46% by 2008, with sales of $24.3 billion, led by Aprovel.

Related Content

No items found

Latest content